Biotechnology issuers that discover and develop biologic, nucleic-acid, gene/cell-therapy, or small-molecule medicines, spanning pre-revenue clinical-stage companies funded primarily by cash on the balance sheet plus collaboration receipts, through commercial-stage biotechs whose revenue is concentrated in one to a small handful of approved franchise products. The disclosure pattern is dominated b
| Ticker | Company | Their metric | Period | YoY | A year ago |
|---|---|---|---|---|---|
| BIIB | Biogen Inc. | Net debt | FY2026-Q1 | -59.5% | -32.7% |
| PBYI | Puma Biotechnology, Inc. | Ex-factory bottles sold | FY2026-Q2 | +12.3% | +3.7% |
| PRGO | Perrigo Company plc | Net Pricing | FY2026-Q2 | -0.1 pts | -4.3 pts |
| HRMY | Harmony Biosciences Holdings, Inc. | Average patients on WAKIX | FY2026-Q2 | +17.8% | +16.0% |
| TEVA | Teva Pharmaceutical Industries Limited | United States generic prescriptions | FY2026-Q2 | -10.9% | -12.2% |
| CYRX | Cryoport, Inc. | Active Cell and Gene Therapy clinical trials supported | FY2026-Q2 | +7.0% | +6.4% |
| EOLS | Evolus, Inc. | Customer Reorder Rate | FY2026-Q2 | +0.0 pts | +0.0 pts |
| DNTH | Dianthus Therapeutics, Inc. | G&A Expenses | FY2026-Q2 | +52.8% | +48.3% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | ARCALYST Prescribers | FY2026-Q2 | +43.9% | +51.1% |
| IRWD | Ironwood Pharmaceuticals, Inc. | Total LINZESS Prescription Demand | FY2026-Q2 | +3.1% | +11.5% |
| AGIO | Agios Pharmaceuticals, Inc. | PYRUKYND Patients on Therapy | FY2025-Q3 | +17.3% | +27.0% |
| JAZZ | Jazz Pharmaceuticals plc | Idiopathic hypersomnia patients | FY2026-Q2 | +26.5% | +40.2% |
| VRTX | Vertex Pharmaceuticals Incorporated | Untreated patients addressable with triple combination | FY2025-Q2 | -75.0% | +0.0% |
| TARS | Tarsus Pharmaceuticals, Inc. | XDEMVY Bottles Delivered to Patients | FY2025-Q4 | +122.2% | +290.0% |
| PHAT | Phathom Pharmaceuticals, Inc. | VOQUEZNA prescriptions filled | FY2026-Q2 | +87.9% | +394.3% |
A side-by-side appears only when three or more companies report the same metric in the same unit under their own definition. Companies are listed in value order, not ranked: whether a higher number is better is not asserted.